Development of integrase inhibitors of quinolone acid derivatives for treatment of AIDS: An overview

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 11, 2010, Pages 1046-1057

  Luo, Z G ^a,b   Tans, J J ^a   Zeng, Y ^a   Wang, C X ^a   Hu, L M ^a  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

^b ANHUI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Diketoacides; Drug discovery; HIV 1; Inhibitors; Integrase; Quinolone acid derivatives

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BETA DIKETOACID; ELVITEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; L 708906; L 870812; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; OXOACID; QUINOLONE; QUINOLONE DERIVATIVE; RALTEGRAVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME STRUCTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; PHARMACOPHORE; PROTEIN FUNCTION; STRUCTURE ACTIVITY RELATION;

EID: 77956627651     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557511009011046     Document Type: Article

References (64)

1. 09 AIDS epidemic update. http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf (Accessed July 4, 2010).
2. Girard, M.P.; Osmanov, S.K.; Kieny, M.P. A review of vaccine research and development: The human immunodeficiency virus (HIV). Vaccine, 2006, 24(19), 4062-81.
3. Tan, J.J.; Cong, X.J.; Hu, L.M.; Wang, C.X.; Jia, L.; Liang, X.J. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discov. Today, 2010, 15(5-6), 186-97.
4. Machouf, N.; Thomas, R.; Nguyen, V.K.; Trottier, B.; Boulassel, M.R.; Wainberg, M.A.; Routy, J.P. Effects of drug resistance on viral load in patients failing antiretroviral therapy. J. Med. Virol., 2006, 78(5), 608-13.
5. Cozzi-Lepri, A.; Phillips, A.N.; Ruiz, L.; Clotet, B.; Loveday, C.; Kjaer, J.; Mens, H.; Clumeck, N.; Viksna, L.; Antunes, F.; Machala, L.; Lundgren, J.D.; Grp, E.S. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS, 2007, 21(6), 721-32.
6. Friis-Moller, N.; Reiss, P.; Sabin, C.A.; Weber, R.; Monforte, A.D.; El-Sadr, W.; De Wit, S.; Kirk, O.; Fontas, E.; Law, M.G.; Phillips, A.; Lundgren, J.D.; Grp, D.S. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med., 2007, 356(17), 1723-35.
7. Delelis, O.; Thierry, S.; Subra, F.; Simon, F.; Malet, I.; Alloui, C.; Sayon, S.; Calvez, V.; Deprez, E.; Marcelin, A.G.; Tchertanov, L.; Mouscadet, J.F. Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In vitro and In vivo. Antimicrob. Agents Chemother., 2010, 54(1), 491-501.
8. Potter, S.J.; Dwyer, D.E.; Saksena, N.K. Differential cellular distribution of HIV-1 drug resistance in vivo: Evidence for infection of CD8+T cells during HAART. Virology, 2003, 305(2), 339-52.
9. Pais, G.C.G.; Zhang, X.C.; Marchand, C.; Neamati, N.; Cowansage, K.; Svarovskaia, E.S.; Pathak, V.K.; Tang, Y.; Nicklaus, M.; Pommier, Y.; Burke, T.R. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J. Med. Chem., 2002, 45(15), 3184-94.
10. Fatkenheuer, G.; Pozniak, A.L.; Johnson, M.A.; Plettenberg, A.; Staszewski, S.; Hoepelman, A.I.M.; Saag, M.S.; Goebel, F.D.; Rockstroh, J.K.; Dezube, B.J.; Jenkins, T.M.; Medhurst, C.; Sullivan, J.F.; Ridgway, C.; Abel, S.; James, I.T.; Youle, M.; van der Ryst, E. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med., 2005, 11(11), 1170-72.
11. Opar, A. New HIV drug classes on the horizon. Nat. Rev. Drug Discovery, 2007, 6(4), 258-59.
12. Dayam, R.; Al-Mawsawi, L.Q.; Neamati, N. HIV-1 Integrase Inhibitors: An Emerging Clinical Reality. Drugs RD, 2007, 8(3), 155-68.
13. Ray, S.; Fatima, Z.; Saxena, A. Drugs for AIDS. Mini-Rev. Med. Chem., 2010, 10(2), 147-61.
14. Wang, Z.Q.; Tang, J.; Salomon, C.E.; Dreis, C.D.; Vince, R. Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase. Bioorg. Med. Chem., 2010, 18(12), 4202-11.
15. Tang, J.; Maddali, K.; Pommier, Y.; Sham, Y.Y.; Wang, Z.Q. Scaffold rearrangement of dihydroxypyrimidine inhibitors of HIV integrase: Docking model revisited. Bioorg. Med. Chem. Lett., 2010, 20(11), 3275-79.
16. Chiu, T.K.; Davies, D.R. Structure and function of HIV-1 integrase. Curr. Top. Med. Chem., 2004, 4(9), 965-77.
17. Hindmarsh, P.; Leis, J. Retroviral DNA integration. Microbiol. Mol. Biol. Rev., 1999, 63(4), 836-+.
18. Nair, V.; Chi, G. HIV integrase inhibitors as therapeutic agents in AIDS. Rev. Med. Virol., 2007, 17(4), 277-95.
19. Marchand, C.; Johnson, A.A.; Semenova, E.; Pommier, Y. Mechanisms and inhibition of HIV integration. Drug Discov. Today Dis. Mech., 2006, 3(2), 253-60.
20. Pommier, Y.; Johnson, A.A.; Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov., 2005, 4(3), 236-48.
21. Bushman, F.D.; Craigie, R. Activities of Human-Immuno-deficiency-Virus (HIV) Integration Protein Invitro - Specific Cleavage and Integration of Hiv DNA. Proc. Natl. Acad. Sci. U. S. A., 1991, 88(4), 1339-43.
22. He, H.Q.; Ma, X.H.; Liu, B.; Chen, W.Z.; Wang, C.X.; Cheng, S.H. A novel high-throughput format assay for HIV-1 integrase strand transfer reaction using magnetic beads. Acta Pharmacol. Sin., 2008, 29(3), 397-404.
23. Pommier, Y.; Marchand, C. Interfacial inhibitors of protein-nucleic acid interactions. Curr. Med. Chem.: Anti-Cancer Agents, 2005, 5(4), 421-29.
24. Goldgur, Y.; Craigie, R.; Cohen, G.H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D.R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc. Natl. Acad. Sci. U. S. A., 1999, 96(23), 13040-43.
25. Espeseth, A.S.; Felock, P.; Wolfe, A.; Witmer, M.; Grobler, J.; Anthony, N.; Egbertson, M.; Melamed, J.Y.; Young, S.; Hamill, T.; Cole, J.L.; Hazuda, D.J. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(21), 11244-49.
26. Grobler, J.A.; Stillmock, K.; Hu, B.H.; Witmer, M.; Felock, P.; Espeseth, A.S.; Wolfe, A.; Egbertson, M.; Bourgeois, M.; Melamed, J.; Wai, J.S.; Young, S.; Vacca, J.; Hazuda, D.J. Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. U. S. A., 2002, 99(10), 6661-66.
27. Marchand, C.; Johnson, A.A.; Karki, R.G.; Pais, G.C.G.; Zhang, X.C.; Cowansage, K.; Patel, T.A.; Nicklaus, M.C.; Burke, T.R.; Pommier, Y. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol. Pharmacol., 2003, 64(3), 600-09.
28. Kawasuji, T.; Fuji, M.; Yoshinaga, T.; Sato, A.; Fujiwara, T.; Kiyama, R. A platform for designing HIV integrase inhibitors. Part 2: A two-metal binding model as a potential mechanism of HIV integrase inhibitors. Bioorg. Med. Chem., 2006, 14(24), 8420-29.
29. Hazuda, D.J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J.A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science, 2000, 287(5453), 646-50.
30. Hazuda, D.J.; Anthony, N.J.; Gomez, R.P.; Jolly, S.M.; Wai, J.S.; Zhuang, L.H.; Fisher, T.E.; Embrey, M.; Guare, J.P.; Egbertson, M.S.; Vacca, J.P.; Huff, J.R.; Felock, P.J.; Witmer, M.V.; Stillmock, K.A.; Danovich, R.; Grobler, J.; Miller, M.D.; Espeseth, A.S.; Jin, L.X.; Chen, I.W.; Lin, J.H.; Kassahun, K.; Ellis, J.D.; Wong, B.K.; Xu, W.; Pearson, P.G.; Schleif, W.A.; Cortese, R.; Emini, E.; Summa, V.; Holloway, M.K.; Young, S.D. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(31), 11233-38.
31. Fikkert, V.; Hombrouck, A.; Van Remoortel, B.; De Maeyer, M.; Pannecouque, C.; De Clercq, E.; Debyser, Z.; Witvrouw, M. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS, 2004, 18(15), 2019-28.
32. Fikkert, V.; Van Maele, B.; Vercammen, J.; Hantson, A.; Van Remoortel, B.; Michiels, M.; Gurnari, C.; Pannecouque, C.; De Maeyer, M.; Engelborghs, Y.; De Clercq, E.; Debyser, Z.; Witvrouw, M. Development of resistance against Diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J. Virol., 2003, 77(21), 11459-70.
33. Shimura, K.; Kodama, E.; Sakagami, Y.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Watanabe, Y.; Ohata, Y.; Doi, S.; Sato, M.; Kano, M.; Ikeda, S.; Matsuoka, M. Broad Antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol., 2008, 82(2), 764-74.
34. Dayam, R.; Detig, F.X.; Neamati, N. HIV-1 integrase inhibitors: 2003-2004 update. Med. Res. Rev., 2006, 26(3), 271-309.
35. Dayam, R.; Gundla, R.; Al-Mawsawi, L.Q.; Neamati, N. HIV-1 integrase inhibitors: 2005-2006 update. Med. Res. Rev., 2008, 28(1), 118-54.
36. Wai, J.S.; Egbertson, M.S.; Payne, L.S.; Fisher, T.E.; Embrey, M.W.; Tran, L.O.; Melamed, J.Y.; Langford, H.M.; Guare, J.P.; Zhuang, L.G.; Grey, V.E.; Vacca, J.P.; Holloway, M.K.; Naylor-Olsen, A.M.; Hazuda, D.J.; Felock, P.J.; Wolfe, A.L.; Stillmock, K.A.; Schleif, W.A.; Gabryelski, L.J.; Young, S.D. 4-aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J. Med. Chem., 2000, 43(26), 4923-26.
37. Nair, V.; Chi, G.; Ptak, R.; Neamati, N. HIV integrase inhibitors with nucleobase scaffolds: Discovery of a highly potent anti-HIV agent. J. Med. Chem., 2006, 49(2), 445-47.
38. Nair, V.; Uchil, V.; Neamati, N. beta-Diketo acids with purine nucleobase scaffolds: Novel, selective inhibitors of the strand transfer step of HIV integrase. Bioorg. Med. Chem. Lett., 2006, 16(7), 1920-23.
39. Hazuda, D.J.; Young, S.D.; Guare, J.P.; Anthony, N.J.; Gomez, R.P.; Wai, J.S.; Vacca, J.P.; Handt, L.; Motzel, S.L.; Klein, H.J.; Dornadula, G.; Danovich, R.M.; Witmer, M.V.; Wilson, K.A.A.; Tussey, L.; Schleif, W.A.; Gabryelski, L.S.; Jin, L.X.; Miller, M.D.; Casimiro, D.R.; Emini, E.A.; Shiver, J.W. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science, 2004, 305(5683), 528-32.
40. Fardis, M.; Jin, H.L.; Jabri, S.; Cai, R.Z.; Mish, M.; Tsiang, M.; Kim, C.U. Effect of substitution on novel tricyclic HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(15), 4031-35.
41. Summa, V.; Petrocchi, A.; Matassa, V.G.; Gardelli, C.; Muraglia, E.; Rowley, M.; Paz, O.G.; Laufer, R.; Monteagudo, E.; Pace, P. 4,5-dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species. J. Med. Chem., 2006, 49(23), 6646-49.
42. Markowitz, M.; Morales-Ramirez, J.O.; Nguyen, B.Y.; Kovacs, C.M.; Steigbigel, R.T.; Cooper, D.A.; Liporace, R.; Schwartz, R.; Isaacs, R.; Gilde, L.R.; Penning, L.; Zhao, J.; Teppler, H.; Team, P.S. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. Acquir. Immunodefic. Syndr., 2006, 43(5), 509-15.
43. Sato, M.; Motomura, T.; Aramaki, H.; Matsuda, T.; Yamashita, M.; Ito, Y.; Kawakami, H.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Ikeda, S.; Kodama, E.; Matsuoka, M.; Shinkai, H. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem., 2006, 49(5), 1506-08.
44. Rosemond, M.J.C.; St John-Williams, L.; Yamaguchi, T.; Fujishita, T.; Walsh, J.S. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem.-Biol. Interact., 2004, 147(2), 129-39.
45. Little, S.; Drusano, G.; Schooley, R.; Haas, D.; Kumar, P.; Hammer, S.; McMahon, D.; Squires, K.; Asfour, R.; Richman, D.; Chen, J.; Saah, A.; Leavitt, R.; Hazuda, D.; Nguyen, B.Y. In The 12th Conference on Retroviruses and Opportunistic Infections: Boston, Massa Chusetts, U. S. A., 2005.
46. Zolopa, A.; Mullen, M.; Berger, D. In The 14th Conference on Retroviruses and Opportunistic Infections: Los Angeles, Calif., U. S. A., 2007.
47. Cecchetti, V.; Fravolini, A.; Lorenzini, M.C.; Tabarrini, O.; Terni, P.; Xin, T. Studies on 6-aminoquinolones: Synthesis and antibacterial evaluation of 6-amino-8-methylquinolones. J. Med. Chem., 1996, 39(2), 436-45.
48. Cecchetti, V.; Clementi, S.; Cruciani, G.; Fravolini, A.; Pagella, P.G.; Savino, A.; Tabarrini, O. 6-Aminoquinolones - a New Class of Quinolone Antibacterials. J. Med. Chem., 1995, 38(6), 973-82.
49. Hagihara, M.; Kashiwase, H.; Katsube, T.; Kimura, T.; Komai, T.; Momota, K.; Ohmine, T.; Nishigaki, T.; Kimura, S.; Shimada, K. Synthesis and anti-HIV activity of arylpiperazinyl fluoroquinolones: A new class of anti-HIV agents. Bioorg. Med. Chem. Lett., 1999, 9(21), 3063-68.
50. Cecchetti, V.; Parolin, C.; Moro, S.; Pecere, T.; Filipponi, E.; Calistri, A.; Tabarrini, O.; Gatto, B.; Palumbo, M.; Fravolini, A.; Palu, G. 6-aminoquinolones as new potential anti-HIV agents. J. Med. Chem., 2000, 43(20), 3799-802.
51. Filipponi, E.; Cruciani, G.; Tabarrini, O.; Cecchetti, V.; Fravolini, A. QSAR study and VolSurf characterization of anti-HIV quinolone library. J. Comput.-Aided Mol. Des., 2001, 15(3), 203-17.
52. Tabarrini, O.; Stevens, M.; Cecchetti, V.; Sabatini, S.; Dell'Uomo, M.; Manfroni, G.; Palumbo, M.; Pannecouque, C.; De Clercq, E.; Fravolini, A. Structure modifications of 6-aminoquinolones with potent anti-HIV activity. J. Med. Chem., 2004, 47(22), 5567-78.
53. Tabarrini, O.; Massari, S.; Daelemans, D.; Stevens, M.; Manfroni, G.; Sabatini, S.; Balzarini, J.; Cecchetti, V.; Pannecouque, C.; Fravolini, A. Structure-activity relationship study on anti-HIV 6-desfluoroquinolones. J. Med. Chem., 2008, 51(17), 5454-58.
54. Massari, S.; Daelemans, D.; Manfroni, G.; Sabatini, S.; Tabarrini, O.; Pannecouque, C.; Cecchetti, V. Studies on anti-HIV quinolones: New insights on the C-6 position. Bioorg. Med. Chem., 2009, 17(2), 667-74.
55. Di Santo, R.; Costi, R.; Roux, A.; Artico, M.; Lavecchia, A.; Marinelli, L.; Novellino, E.; Palmisano, L.; Andreotti, M.; Amici, R.; Galluzzo, C.M.; Nencioni, L.; Palamara, A.T.; Pommier, Y.; Marchand, C. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: Design, synthesis, biological activities, and mechanism of action. J. Med. Chem., 2006, 49(6), 1939-45.
56. Di Santo, R.; Costi, R.; Roux, A.; Miele, G.; Crucitti, G.C.; Iacovo, A.; Rosi, F.; Lavecchia, A.; Marinelli, L.; Di Giovanni, C.; Novellino, E.; Palmisano, L.; Andreotti, M.; Amici, R.; Galluzzo, C.M.; Nencioni, L.; Palamara, A.T.; Pommier, Y.; Marchand, C. Novel quinolinonyl diketo acid derivatives as HIV-1 integrase inhibitors: Design, synthesis, and biological activities. J. Med. Chem., 2008, 51(15), 4744-50.
57. Vandurm, P.; Cauvin, C.; Guiguen, A.; Georges, B.; Le Van, K.; Martinelli, V.; Cardona, C.; Mbemba, G.; Mouscadet, J.F.; Hevesi, L.; Van Lint, C.; Wouters, J. Structural and theoretical studies of [6-bromo-1-(4-fluorophenylmethyl)-4(1H)-quinolinon-3-yl)]-4-hydroxy-2-oxo-3-butenoic acid as HIV-1 integrase inhibitor. Bioorg. Med. Chem. Lett., 2009, 19(16), 4806-09.
58. Sato, M.; Kawakami, H.; Motomura, T.; Aramaki, H.; Matsuda, T.; Yamashita, M.; Ito, Y.; Matsuzaki, Y.; Yamataka, K.; Ikeda, S.; Shinkai, H. Quinolone Carboxylic Acids as a Novel Monoketo Acid Class of Human Immunodeficiency Virus Type 1 Integrase Inhibitors. J. Med. Chem., 2009, 52(15), 4869-82.
59. Pasquini, S.; Botta, L.; Scincraro, T.; Mugnaini, C.; Ligresti, A.; Palazzo, E.; Maione, S.; Di Marzo, V.; Corelli, F. Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo. J. Med. Chem., 2008, 51(16), 5075-84.
60. Didierjean, J.; Isel, C.; Querre, F.; Mouscadet, J.F.; Aubertin, A.M.; Valnot, J.Y.; Piettre, S.R.; Marquet, R. Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones. Antimicrob. Agents Chemother., 2005, 49(12), 4884-94.
61. Wang, Z.Q.; Vince, R. Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase. Bioorg. Med. Chem. Lett., 2008, 18(4), 1293-96.
62. Sechi, M.; Rizzi, G.; Bacchi, A.; Carcelli, M.; Rogolino, D.; Pala, N.; Sanchez, T.W.; Taheri, L.; Dayam, R.; Neamati, N. Design and synthesis of novel dihydroquinoline-3-carboxylic acids as HIV-1 integrase inhibitors. Bioorg. Med. Chem., 2009, 17(7), 2925-35.
63. Dayam, R.; Al-Mawsawi, L.Q.; Zawahir, Z.; Witvrouw, M.; Debyser, Z.; Neamati, N. Quinolone 3-carboxylic acid pharmacophore: Design of second generation HIV-1 integrase inhibitors. J. Med. Chem., 2008, 51(5), 1136-44.
64. Zeng, J.; Lu, X.H.; Zeng, C.C.; Hu, L.M.; Zhong, R.G. Design, Synthesis and Anti-HIV Integrase Evaluation of 1,2,3-Triazol-4-yl-substituted 1,4-Dihydro-4-oxo-1,5-napthyridine-3-carboxylic Acids. Chin. J. Chem., 2009, 27(5), 953-62.